Yes, Fiasp and Tresiba Can Be Used Together
Yes, you can absolutely take Fiasp (insulin aspart) and Tresiba (insulin degludec) together in a basal-bolus regimen for diabetes management. This combination is explicitly supported by current diabetes treatment guidelines and FDA-approved clinical trials.
Evidence Supporting Combined Use
FDA-Approved Clinical Trials
The FDA label for Fiasp directly demonstrates this combination's safety and efficacy. In a pediatric study (Study E), Fiasp was specifically evaluated in combination with insulin degludec (Tresiba) in 777 pediatric patients with type 1 diabetes over 26 weeks 1. This establishes clear regulatory approval for using these two insulins together.
Guideline-Based Recommendations
The 2023 and 2024 ADA Standards of Care explicitly endorse this approach. When basal insulin alone (like Tresiba) fails to achieve glycemic targets, adding rapid-acting insulin analogues (including aspart/Fiasp) before meals is a standard intensification strategy 2, 3. The guidelines specifically mention:
- Adding rapid-acting insulin analogues (lispro, aspart, or glulisine) to basal insulin therapy
- Starting with a single prandial dose before the largest meal
- Advancing to full basal-bolus regimens with 2 or more prandial injections as needed
How This Regimen Works
Tresiba provides:
- Ultra-long-acting basal (background) insulin coverage lasting >42 hours
- Once-daily dosing for consistent baseline glucose control
Fiasp provides:
- Ultra-rapid-acting mealtime (prandial) insulin coverage
- Faster onset than standard rapid-acting insulins
- Dosed 0-2 minutes before meals or up to 20 minutes after starting meals
Clinical Considerations
When to Use This Combination
This basal-bolus approach is indicated when 4, 2:
- Basal insulin has been titrated to acceptable fasting glucose (or dose >0.5 units/kg/day)
- HbA1c remains above target despite optimized basal insulin
- Patient requires both fasting and postprandial glucose control
Dosing Strategy
- Continue metformin when initiating this combination 4, 2
- Discontinue or reduce sulfonylureas and DPP-4 inhibitors to avoid unnecessary complexity and hypoglycemia risk 4, 3
- Start Fiasp at 4 units, 0.1 units/kg, or 10% of basal dose per meal 5
- If HbA1c <8% when starting prandial insulin, consider decreasing Tresiba dose 5
Key Advantages
- Greater meal flexibility compared to premixed insulins 4
- Superior postprandial glucose control with Fiasp's ultra-rapid action 6, 7
- Physiologic insulin replacement mimicking normal pancreatic function
Important Caveats
Hypoglycemia monitoring: While this combination is effective, both insulins can cause hypoglycemia. The ultra-rapid action of Fiasp requires careful meal timing and carbohydrate counting.
Dose titration is critical: Adjustments in both basal and prandial components are necessary based on blood glucose patterns 4, 2. This requires understanding each insulin's pharmacodynamic profile—Tresiba affects fasting glucose, while Fiasp affects postprandial glucose.
Not a premixed product: Unlike the 70/30 degludec/aspart premixed formulation mentioned in guidelines 4, Fiasp and Tresiba are administered as separate injections, allowing independent dose adjustments for optimal control.
This basal-bolus combination represents standard-of-care diabetes management and is fully supported by both regulatory approval and clinical practice guidelines 2, 1.